What question did this study set out to answer?

This study aims to compare long-term outcomes in esophageal and esophagogastric junction adenocarcinoma patients who achieved pathological complete response after neoadjuvant chemotherapy versus chemoradiotherapy.

July 29, 2026Annals of Surgical OncologyOpen Access

Beyond Pathological Complete Response: Long-term Outcomes in Esophageal and Esophagogastric Junction Adenocarcinoma After Multimodal Therapy—A Systematic Review and Individual Patient-Data Meta-Analysis

View Full Paper

Ask AI

Bookmark

This study aims to compare long-term outcomes in esophageal and esophagogastric junction adenocarcinoma patients who achieved pathological complete response after neoadjuvant chemotherapy versus chemoradiotherapy.
Conducted a systematic review of literature through PubMed and Embase until November 2025.
Identified studies comparing neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy in patients with esophageal or EGJ adenocarcinoma and pathological complete response.
Performed an individual patient-data meta-analysis for overall and disease-free survival.
In 1454 patients, 1-, 3-, and 5-year overall survival rates were 95.4%, 81.5%, and 73.8% for neoadjuvant chemotherapy, compared to 87.8%, 64.8%, and 56% for neoadjuvant chemoradiotherapy (p < 0.001).
Disease-free survival was also superior in the neoadjuvant chemotherapy group at all time points (p < 0.001).
Neoadjuvant chemotherapy was associated with a decreased risk of death (HR = 0.49, p < 0.001) and recurrence (HR = 0.24, p < 0.001).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Systematic review compares long-term survival outcomes in esophageal adenocarcinoma after different therapies, indicating important treatment implications.

Cite This Study

Risi et al. (2026) studied this question.

synapsesocial.com/papers/6a69a27dc8da07d9defa5f9c https://doi.org/10.1245/s10434-026-20296-x

View Full Paper

Ask AI

Bookmark

Implication

Systematic review compares long-term survival outcomes in esophageal adenocarcinoma after different therapies, indicating important treatment implications.

Beyond Pathological Complete Response: Long-term Outcomes in Esophageal and Esophagogastric Junction Adenocarcinoma After Multimodal Therapy—A Systematic Review and Individual Patient-Data Meta-Analysis

Key Points

Discussion

Implication

Cite This Study

Beyond Pathological Complete Response: Long-term Outcomes in Esophageal and Esophagogastric Junction Adenocarcinoma After Multimodal Therapy—A Systematic Review and Individual Patient-Data Meta-Analysis

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider